FRIDAY, April 3, 2020 — Deep early remission of Crohn disease is associated with a significant decrease in long-term adverse effects, according to a study published online March 26 in Gastroenterology.
Ryan C. Ungaro, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues used follow-up data from 122 patients (mean age, 31.2 years) with early, moderate-to-severe Crohn disease (median duration, 0.2 years) who had participated in the randomized trial the Effect of Tight Control Management on Crohn Disease (CALM) at 31 sites.
During a median three-year follow-up period, the researchers found that major adverse outcomes were reported for 27.9 percent of patients. Significantly fewer patients in deep remission at the end of the CALM study (defined as Crohn disease endoscopic index of severity scores less than 4, with no deep ulcerations or steroid treatment, for at least eight weeks) had major adverse outcomes during the follow-up period. Deep remission was significantly associated with a lower risk for major adverse outcomes when adjusting for potential confounders (adjusted hazard ratio, 0.19).
“The data suggests strongly that achieving deep remission early in the course of Crohn disease can lead to disease modification with a significant decrease in long-term complications,” Ungaro said in a statement.
Several authors reported financial ties to pharmaceutical companies, including AbbVie, which funded the CALM clinical trial.
© 2020 HealthDay. All rights reserved.
Posted: April 2020